Cancer Research  09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 23, 1762-1768, December 1, 1963]
© 1963 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Booth, B. A.
Right arrow Articles by Sartorelli, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Booth, B. A.
Right arrow Articles by Sartorelli, A. C.

Growth Inhibition of a Spectrum of Transplanted Mouse Tumors by Combinations of Inhibitors of Nucleic Acid biosynthesis and Alkylating Agents*

Barbara A. Booth and Alan C. Sartorelli

( Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut)

The tumor-inhibitory potency of combinations of uracil mustard and 6-thioguanine was measured in seven transplanted mouse neoplasms; pronounced inhibition occurred in five of the tumors. Maximum effectiveness of the combination occurred when simultaneous administration of the two drugs was employed; separation of dosages by an interval of 12 hours resulted in a marked reduction in activity. A monofunctional uracil mustard was not inhibitory by itself, nor did it enhance the tumor-inhibitory potency of 6-thioguanine in Sarcoma 180, a neoplasm sensitive to the difunctional mustard.

5-Fluorouracil, 5-iodo-2'-deoxyuridine, and 6-chloropurine potentiated the carcinolytic effects of uracil mustard; at the dose levels employed, 5-iodo-2'-deoxycytidine and 6-mercaptopurine produced borderline results, whereas 8-azaguanine, 6-azauridine, and azaserine did not enhance the tumor-inhibitory activity of uracil mustard on Sarcoma 180. Nitrogen mustard-thioguanine combinations produced at least an additive effect, whereas cyclophosphamide, chlorambucil, thio TEPA1 and Myleran did not add to the 6-thioguanine-induced inhibition of this neoplasm.

* This research was supported by a grant (CA-02817) from the National Cancer Institute, Public Health Service.

1 The following abbreviations are used: DNA, deoxyribonucleic acid; RNA, ribonucleic acid; thioTEPA, N,N',N''-triethylenethiophosphoramide; Myleran, 1,4-(dimethanesulfonoxy)butane; chlorambucil, p-N,N-di(ß-chloroethyl)aminophenylbutyric acid; nitrogen mustard, methylbis(ß-chloroethyl)amine; cyclophosphamide, N,N-bis(ß-chloroethyl)-N', O-propylenephosphoric acid ester diamide; dopan, 5-[bis(ß-chloroethyl)amino]-6-methyluracil.

Received 6/20/63.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1963 by the American Association for Cancer Research.